Kroger has announced a new vaccine for Astrazenea, which it says will prevent the deadly coronavirus coronaviruses.
It is the first time the US vaccine maker has released a vaccine for the COVID-19 pandemic.
Kroger said it has received approval from the US Food and Drug Administration for the vaccine, which has a vaccine efficacy of 94%.
The Astrazenek vaccine is an eight-dose, double-blind, placebo-controlled, multi-centre trial, and will be given in the United States starting in late 2019.
In November, the company said it had received FDA approval to start distributing the vaccine to hospitals, clinics and pharmacies.
The Astrazanes vaccine is designed to help prevent COVID and other infections caused by coronavirevirus.
The company is working with health officials in more than a dozen countries to distribute the vaccine.
Astrazenax was originally launched by AstraZeneca, a US company, in 2009.
The UK-based company has since acquired all but one of its shares, in part to strengthen its US-based operations.
In 2018, Astrazenay announced a second phase of its vaccine, known as COVID20, and said it planned to begin delivering it to hospitals in late 2021.
In the United Kingdom, Astrazeneca and Merck’s Bristol-Myers Squibb have both said they will begin delivering the COVE-19 vaccine by mid-2019.
In late March, Astrazax announced a $2.3 billion deal with the UK’s private insurance giant, the Royal College of Physicians, to launch COVID19 vaccines in 2020.
The new Astrazenac vaccine is part of a plan to help bring COVID to as many people as possible, with the goal of having an eventual vaccine for all the COVENs in the world by the middle of the next decade.
“We are excited to announce a new Astrazano vaccine for COVID in the U.K.,” the company tweeted on Tuesday.
“A trial in the UK is underway and we will share more information as we get closer.”